This website will continue to be updated as new information becomes available.

We are pleased to share that the FDA has updated the status of Wegovy® to “Resolved” on their drug shortage website, indicating that the supply of this prescription-only GLP-1 medicine now meets or exceeds current and projected demand in the U.S., and that all doses of Wegovy® are being shipped regularly to our customers.  This update comes after ongoing dialogue with the FDA and substantial efforts by Novo Nordisk to increase manufacturing capacity, including $6.5 billion of investments in the US in 2025.

Know that at Novo Nordisk, patients are our top priority, and we will never stop working and advocating for those who need our medicines. We are grateful for the trust that patients, healthcare professionals, and others have put in Novo Nordisk and thank them for their patience as we worked  to meet the high demand for this medicine. This resolution marks an important milestone in ensuring those living obesity have access to critical medication, demonstrating that our efforts to increase capacity have worked, and underscores our commitment to delivering for those that can benefit from Wegovy®.

We will continue to prioritize continuity of care for patients, closely monitoring market dynamics and prescribing trends along the way to ensure people do not have to turn to fake and potentially unsafe Wegovy®.

Click here for an overview of how Wegovy® is made, manufactured, and shipped.

Important Guidance: Filling Your Wegovy® Prescription

  • It is important to note that even when a medication is available, patients may not always be able to immediately fill their prescription at a particular pharmacy.
  • Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage due to factors like ordering practices, logistics, and retailer capacity constraints.
  • If you are unable to obtain your specific dose strength, we encourage you to try other local pharmacies for availability. In many cases, the dose can be ordered to arrive within 2 business days.
  • In instances where you are not able to immediately fill a prescription, you can use our Find My Meds app that helps patients with finding and filling their prescribed Wegovy® so they can focus on their treatment goals. By making it easier for patients to locate and secure their prescribed medication, the app helps to reduce interruptions in therapy, which may improve adherence. Visit www.findmymedsapp.com to learn more.

As always, we encourage you to speak with your healthcare professional if you have questions about your treatment plan or concerns about continuity of care. Healthcare professionals know their patients' past and current medical history and are best equipped to make clinical recommendations.

Novo Nordisk is deeply concerned about the proliferation of fake and illegitimate compounded "semaglutide" and the risks they pose to patients. In addition to the FDA, numerous patient advocacy organizations, medical experts,  government officials and regulators are also sounding the alarm. These collective voices are calling for urgent action to protect public health. When it comes to fake, illegitimate Wegovy®, consumers don’t know what’s in the vials - but whatever it is, it’s not FDA-approved.

It's crucial to understand that compounded semaglutide has not been proven safe or effective. The FDA action around the resolution of the previous supply challenge should significantly restrict what compounders can legally do and Novo Nordisk intends to hold them accountable consistent with our commitment to patient safety.

As makers of the only real FDA-approved semaglutide medicines like Wegovy®, patient safety remains our top priority. We are committed to confronting the stigma linked with chronic diseases, like obesity, and expanding access to our authentic, prescription-only medicines.

Please see important information, including the Prescribing Information, for our semaglutide products and up to date information on the responsible use of our semaglutide products at semaglutide.com.

We remain committed to driving meaningful change for people living with obesity and supporting healthcare professionals partnering on their care. As part of this commitment, we want to ensure that Wegovy® is used properly and responsibly for the treatment of obesity in consultation with a licensed healthcare professional.

Wegovy® is the only semaglutide-containing Novo Nordisk medication approved by the U.S. Food and Drug Administration (FDA) for chronic weight management in adults with obesity or overweight with weight-related medical problems and for adults living with obesity and known heart disease. This prescription-only medicine is available in a disposable single-use pen and should be prescribed in direct consultation with, and under the supervision of, a licensed healthcare professional. We support these medicines being prescribed to patients who meet the FDA-approved criteria and promote our medicines for those appropriate patients. Our other semaglutide-based products, Ozempic® (semaglutide) injection 0.5 mg, 1 mg, or 2 mg and Rybelsus® (semaglutide) tablets 7 mg or 14 mg, which are indicated for adults with type 2 diabetes, have unique safety and efficacy profiles and are not FDA-approved for chronic weight management.

At Novo Nordisk, we are dedicated to addressing the unmet medical needs of people living with obesity worldwide. This commitment is underscored by our substantial increase in access, ensuring the broadest reach and impact of GLP-1 RAs across the globe. Since 2021, Novo Nordisk has successfully launched Wegovy® in more than ten countries with more approvals and launches expected in the future.

Increasing our manufacturing capacity is a key factor in our ability to produce more medicines and we continue to expand our global production capacity, which has been running 24 hours a day, seven days a week.

Since the beginning of 2023, Novo Nordisk has committed to spending over $30 billion on expanding our manufacturing capacity, including the expansion of our production facility in North Carolina in June 2024, to grow our ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. 

In late 2024, Novo Nordisk completed its acquisition of three manufacturing sites from Novo Holdings A/S. The acquisition supports Novo Nordisk’s strategy to serve more patients by expanding manufacturing capacity to meet the demand for current and future obesity products. The newly acquired sites are expected to gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.

If you are interested in Wegovy®, please discuss with your healthcare professional (HCP) if it might be right for you.

To see if Wegovy® is covered by your insurance, visit Wegovy.com or contact your insurance provider.

 

We’ve included some frequently asked questions below and are here to help if you need additional support at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Time Monday through Friday – and select option 0 for more support and at Wegovy.com.

  • to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
  • that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.

All doses of Wegovy® are being shipped regularly to our customers and we are pleased to share that the FDA has moved the status of Wegovy® to “Resolved” on their shortage website, indicating that the supply of this prescription-only GLP-1 medicine now meets or exceeds current and projected demand in the U.S.

We are running our manufacturing lines 24 hours a day, seven days a week, manufacturing more Wegovy® than ever before and each does strength of Wegovy® is being shipped regularly to wholesalers.

We have taken steps to help support stable supply so that patients have access to these important medicines. We will continue to prioritize continuity of care for patients, closely monitoring market dynamics and prescribing trends along the way so people do not have to turn to potentially unsafe compounded knockoffs. It is important to note that even when a medication is available, patients may not always be able to immediately fill their prescription at a particular pharmacy. Patients may experience variability at a particular pharmacy location regardless of whether a drug is in shortage.

Increasing our manufacturing capacity is a key factor in our ability to produce more medicines and we continue to expand our global production capacity, which has been running 24 hours a day, seven days a week. In late 2024, we acquired three manufacturing sites that are expected to gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.

Although Wegovy® and Ozempic® both contain semaglutide, they are different products with different indications, dosages, prescribing information, and titration schedules, as approved by the FDA. Each medication has a unique safety and efficacy profile, which is detailed in its respective product label. The products are not interchangeable. We support our medicines being prescribed to patients who meet the indicated criteria and only promote the FDA-approved indications of our medicines for appropriate patients. Click here to read more about our commitment to the responsible use of our medicines.

Knockoff versions of "semaglutide" pose significant threats to people’s health and safety with respected medical organizations and experts raising serious concerns about these illegitimate offerings that abuse the original intent of compounding. This includes groups like the American Medical Association, the American Diabetes Association (ADA), and the Endocrine Society. The ADA recommends against using these knock-off versions due to uncertainty about their content, safety, quality, and effectiveness. These knock-off offerings have been shown to contain dangerous impurities, substances that are on the FDA banned list and incorrect amounts of the core ingredient. Further, the ingredients in those knock-off products are commonly produced in facilities that lack FDA “approval” or “authorization” to manufacture semaglutide for use in compounding. Learn more about the significant safety and health risks associated with compounded or knock-off "semaglutide" on semaglutide.com.

It's crucial to understand that compounded semaglutide has not been proven safe or effective. The FDA action around the resolution of the previous supply challenge should significantly restrict what compounders can legally do and Novo Nordisk intends to hold them accountable consistent with our commitment to patient safety.

Novo Nordisk is taking robust and proactive measures to protect patients and warn them about the dangers of non-FDA approved knock-off versions of "semaglutide", including actively correcting misinformation and educating communities about the risks of knockoff semaglutide, taking legal action where necessary to fight misinformation and uphold patient safety standards and conducting extensive testing of samples to better understand safety risks. We've also nominated semaglutide to the FDA’s lists of medicines that are too complex to compound, known as the "DDC Lists". Our ongoing efforts, detailed on semaglutide.com, are geared toward protecting patients and ensuring they have access to safe and effective FDA-approved medicines. Protecting people from knockoff versions of "semaglutide" is part of our long-term commitment to people living with obesity and the healthcare professionals partnering on their care.

  • to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight
  • that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.

Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.

It is not known if Wegovy ® is safe and effective for use in children under 12 years of age.

  • Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people 
  • Do not use Wegovy ® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

  • you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy ® 

  • have or have had problems with your pancreas or kidneys
  • have type 2 diabetes and a history of diabetic retinopathy
  • have or have had depression, suicidal thoughts, or mental health issues
  • are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
  • are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
  • are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk

Tell your healthcare professional about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare professional if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.

 

  • inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare professional right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
  • gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare professional if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay colored stools
  • increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare professional about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
  • kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
  • severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away
  • serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
  • change in vision in people with type 2 diabetes. Tell your healthcare professional if you have changes in vision during treatment with Wegovy®
  • increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare professional if you feel your heart racing or pounding in your chest and it lasts for several minutes
  • depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare professional right away if you have any mental changes that are new, worse, or worry you
  • food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures

 

The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, gas, stomach flu, heartburn, and runny nose or sore throat.

If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. 

Let us know! Please rate your experience with this page. *

{{crossValidationError['Was this page helpful'].crossValidationErrorMessage}}
© 2023 Novo Nordisk All rights reserved. : US25OB00137 February 2025